|Ritonavir||Protease inhibitor (pharmacokinetic booster)|
|Other names||Anzavir-R, ritonavir/atazanavir|
|Defined daily dose||0.3 gram|
Atazanavir/ritonavir (ATV/r) is a fixed-dose combination medication used in the treatment of HIV/AIDS. It combines atazanavir and ritonavir. It may be used instead of lopinavir/ritonavir. It is taken by mouth.
Side effects are generally minimal. They may include abdominal pain, diarrhea, yellowish skin, muscle pains, and headache. Greater care should be taken in people with underlying liver problems. Use in pregnancy appears to be safe. In the combination atazanavir functions as a protease inhibitor and ritonavir functions to increase levels of atazanavir.
The combination was approved for use in India in 2012, and is pending approval in the United States As of 2017[update]. It is on the World Health Organization's List of Essential Medicines. The average cost per year is 281 USD in the developing world as of 2012.
- "Atazanavir/ritonavir - Mylan Laboratories - AdisInsight". adisinsight.springer.com. Retrieved 29 June 2017. CS1 maint: discouraged parameter (link)
- "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 12 September 2020. CS1 maint: discouraged parameter (link)
- "Atazanavir + ritonavir (Addition) -- Adults". World Health Organization (WHO). Retrieved 29 June 2017. CS1 maint: discouraged parameter (link)
- "Atazanavir/Ritonavir in Pregnancy". hivinsite.ucsf.edu. Retrieved 10 December 2017. CS1 maint: discouraged parameter (link)
- World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.